Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer

PURPOSE: (18)F-fluoroestradiol (FES) positron emission tomography (PET) scans measure regional estrogen binding, and (18)F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined quantitative and qualitative imaging biomarkers of progression-free survival in breast cancer patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Kurland, Brenda F., Peterson, Lanell M., Lee, Jean H., Schubert, Erin K., Currin, Erin R., Link, Jeanne M., Krohn, Kenneth A., Mankoff, David A., Linden, Hannah M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5183531/
https://ncbi.nlm.nih.gov/pubmed/27342400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0362
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados